REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022, at 1:30 p.m. ET in New York, NY. The company will conduct a fireside chat, accessible via a live webcast on its website, with an archived version available for about 30 days post-event. REGENXBIO is recognized for its gene therapy advancements, utilizing its proprietary NAV Technology Platform comprising over 100 AAV vectors. The firm aims to progress five gene therapy programs into pivotal stages or commercial products by 2025.
Positive
- Participation in a reputable industry conference enhances visibility.
- Showcases commitment to advancing gene therapy through public engagement.
Negative
- None.
News Market Reaction – RGNX
In the trading session that priced this news, RGNX gained 4.04%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:
Chardan's 6th Annual Genetic Medicines Conference
Date: Tuesday, October 4th, 2022
Fireside chat: 1:30 p.m. ET
Location: Westin Grand Central, New York, NY
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-6th-annual-genetic-medicines-conference-301633825.html
SOURCE REGENXBIO Inc.